Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Neurocrine Biosciences, through Sigma Merger Sub, Inc., has commenced a tender offer to purchase all outstanding shares of Soleno Therapeutics, Inc. common stock. The offer price is $53.00 per Share, payable in cash without interest, subject to reduction for applicable withholding taxes.
The filing is made on Schedule TO under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act, and it references an offer to purchase dated April 20, 2026 and a related letter of transmittal. The tender offer is for all of Soleno’s outstanding common stock, par value $0.001 per share.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026